ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. The drug, called evorpacept, is in a pair of phase 2 trials for ...
They feed us, entertain us, take care of our health, grow the economy, seek equity and justice — and they give us hope. We Are ALX calls them unsung heroes, civic leaders, and business trailblazers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback